Tirzepatide

Dual GIP and GLP-1 receptor agonist. Produces superior weight loss and glycemic control vs Semaglutide.

Route: SubQShelf life once mixed: ~56 daysCategory: Metabolic / Weight Loss

What Tirzepatide is

Tirzepatide functions as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both these incretin receptors, it synergistically enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon secretion from alpha cells, particularly after meals. This dual action also contributes to a delay in gastric emptying, which helps to moderate postprandial glucose excursions and promotes a feeling of satiety. Its molecular structure provides for an extended pharmacokinetic profile, resulting in an approximate half-life of five days in humans, supporting once-weekly administration.

In research settings, tirzepatide is typically administered subcutaneously, with studies often involving a dose titration schedule starting from lower doses and gradually increasing up to the maximum dose over several weeks to assess tolerability and efficacy. Effects on satiety and glycemic parameters may become noticeable within weeks, with more significant alterations in body weight and long-term glycemic control typically observed over research periods spanning several months. Research has indicated that tirzepatide can produce superior outcomes in both weight reduction and glycemic management compared to single GLP-1 receptor agonists like semaglutide. It is important to remember that tirzepatide is a research peptide and is not intended for self-administration or medical use outside of a supervised research or clinical trial context.

Commonly reported effects

Aggressive fat loss
Appetite reduction
Insulin sensitivity

Reported side effects & considerations

Nausea
Vomiting
Diarrhea
Gallbladder issues

Storage & handling

LYOPHILIZED (unopened): store at 2-8°C (fridge) or -20°C (freezer) long-term. Protect from light.

AFTER RECONSTITUTION: refrigerate 2-8°C. Do NOT freeze. Discard after 56 days OR if the solution becomes cloudy, discolored, or contains particulates.

What people track

Because individual responses vary so much, the useful thing is your own record: what you logged and when, how much is left in the vial, and how your chosen metrics move over the weeks. Peptide Wizard keeps all of that in one place, alongside a 3D reference vial for Tirzepatide.

FAQ

What is Tirzepatide?

Dual GIP and GLP-1 receptor agonist. Produces superior weight loss and glycemic control vs Semaglutide.

What do people commonly report with Tirzepatide?

Commonly reported effects include aggressive fat loss, appetite reduction, insulin sensitivity.

How should Tirzepatide be stored?

LYOPHILIZED (unopened): store at 2-8°C (fridge) or -20°C (freezer) long-term. Protect from light.

How do I keep track of Tirzepatide in my research log?

Peptide Wizard lets you record each entry, keep a vial ledger so you know what's left, and chart your own metrics over time. It is a logbook and reference only — it does not calculate or recommend doses.